Elan Corp is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of Elan Corp in the market include Biogen Inc., Novartis AG, Takeda Pharmaceutical Company Limited, and Amgen Inc.

Elan Corp is a renowned pharmaceutical company with a rich history and background. Established in 1969, it has grown into a global player in the biotechnology industry. Elan Corp focuses on developing innovative therapies for various medical conditions, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Over the years, the company has gained recognition for its cutting-edge research and development initiatives. With a strong commitment to improving patient outcomes, Elan Corp has built a reputation for delivering high-quality products that address critical unmet medical needs. Today, it continues to prioritize advancements in healthcare through its dedicated team of scientists, researchers, and healthcare professionals.

Elan Corp, a leading pharmaceutical company, has achieved numerous significant milestones. One of the notable achievements includes the development and launch of Tysabri, a breakthrough treatment for multiple sclerosis. Another milestone is the successful collaboration with Biogen on Tysabri, which showcased the company's strong expertise in partnerships. Elan Corp has also embarked on several successful acquisitions, such as its merger with Perrigo in 2013, expanding its portfolio and global reach. Moreover, the company's dedication to innovation is evident through continuous research and development efforts, leading to the advancement of novel therapies in various therapeutic areas.

Elan Corp is primarily present in multiple countries and regions worldwide. With a global presence, the company operates in various key markets, including the United States, Ireland, and other parts of Europe. Additionally, Elan Corp has established a prominent presence in emerging markets such as Asia and Latin America, further expanding its reach and potential for growth. By strategically expanding their operations across different geographies, Elan Corp aims to tap into diverse markets and leverage regional opportunities to drive success and enhance shareholder value.

Elan Corp represents values of innovation, collaboration, and patient-centered focus. The company's corporate philosophy emphasizes the development of groundbreaking therapies and solutions to improve the lives of patients worldwide. With an extensive portfolio of research and development, Elan Corp aims to lead the way in healthcare advancements, ensuring excellence in quality, safety, and efficacy of its products. By leveraging its expertise and strategic partnerships, Elan Corp strives to make a positive impact on the healthcare industry and contribute to the betterment of society.

Analysts currently set an average price target of 1 020,00 JPY for the Elan stock (median: 1 020,00 JPY), implying +37,3 % versus the latest price. The consensus is based on 6 analyst ratings.

Elan Analyytikkojen kursstavoitteet 2026

7 analysts currently rate the Elan stock: 0 recommend buying, 3 holding and 4 selling. For 2026, analysts expect Elan to generate revenue of 60,60 Mrd. JPY and earnings per share of 52,60 JPY.

Elan Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Elan share trades at 4,22 EUR (764,00 JPY).

The Elan share (6099.T) is listed on 2 stock exchanges, including: Frankfurt (25E.F).

Elan Corp is an Irish pharmaceutical company that focuses on the development, manufacturing, and marketing of specialized medicines. It serves both the US and European markets with a focus on unmet medical needs and innovative technologies. The article describes Elan's business model, key business areas, and products as well as its market orientation. Elan Corp's business model encompasses the entire value chain from research and development to production and sales of pharmaceutical products. The company focuses on developing and licensing innovative technologies in the medical industry and has a coordinated and differentiated product portfolio. Elan Corp operates three business areas: biopharmaceuticals, product innovations, and Elan Drug Technologies (EDT). The biopharmaceuticals division specializes in developing drugs for neurodegenerative diseases such as Alzheimer's, Parkinson's, and multiple sclerosis, with Tysabri being a well-known product in this area. The product innovations division conducts an intensive research and development program aimed at discovering and launching new products. The EDT division offers a variety of patented and innovative technologies for improving drug delivery and absorption. Elan offers a wide portfolio of medications for the treatment of neurodegenerative diseases, autoimmune diseases, and cancer. The company provides various products and technologies, including proprietary technologies for enhancing drug efficacy and reducing adverse effects, for the therapy of various diseases and medical conditions. Elan Corp specializes in the development of Tysabri, a medication for the treatment of multiple sclerosis. It is a monoclonal antibody drug administered as an infusion that slows disease progression and reduces the frequency of relapses. Elan Corp is an internationally operating company specializing in the US and European markets. It particularly relies on targeted local marketing and sales strategies to expand its customer base and provide comprehensive product information. In summary, Elan Corp focuses on the development and marketing of medications for the treatment of neurodegenerative diseases, cancer, and autoimmune diseases. The company operates a coordinated portfolio and utilizes patented technologies to improve drug efficacy and reduce adverse effects. Elan has particularly focused on the US and Europe and is known in the industry as an innovative, future-oriented provider.

odotettu liikevaihto Elan on 60,60 Mrd. JPY. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Elan on 3,18 Mrd. JPY. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Elan:n hinta-voitto-suhde (P/E) on tällä hetkellä 14,52. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Elan-osakkeen arvostusta.

Elan:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,76. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Elan-osakkeen arvostuskennuslukuna.

Elan:n Eulpool-laatuscore on 8/10.

Elan:n ISIN on JP3167680002. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Elan:n WKN on A12C13. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Elan:n ticker on 6099.T. Tämä pörssinoteeraus käytetään Elan-osakkeiden kauppaan pörssissä.

Viimeisten 12 kuukauden aikana Elan maksoi osinkoa 15,00 JPY . Tämä vastaa osingontuottoa noin 1,96 %. Tulevien 12 kuukauden aikana Elan odotetaan maksavan osinkoa 28,00 JPY.

Elan:n nykyinen osinkotuotto on 1,96 %.

Elan maksaa osinkoa, joka jaetaan kuukausina , , , .

Elan maksoi osinkoa joka vuosi viimeisten 12 vuoden aikana.

Tulevien 12 kuukauden aikana odotetaan osinkoja, joiden määrä on 28,00 JPY. Tämä vastaa osingontuottoa 3,66 %.

Elan kuuluu sektoriin 'Terveydenhuolto'.

Saadaksesi viimeisen osingon Elan:sta päivältä määrässä 15 JPY, sinulla piti olla osake portfoliossasi ennen irtoamispäivää .

Viimeinen osinko maksettiin .

Vuonna 2025 Elan jakoi 13 JPY osinkona.

Elan:n osingot jaetaan valuutassa JPY.